Annovis Bio Inc
ANVS2.615USD
+0.105+4.18%
Market hours （ET）Quotes delayed by 15 min
50.96MMarket Cap
LossP/E TTM
More Details of Annovis Bio Inc Company
Annovis Bio, Inc. is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and other chronic neurodegenerative diseases. The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury (TBI) and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from six to three.
Company Info
Ticker SymbolANVS
Company nameAnnovis Bio Inc
IPO dateJan 29, 2020
CEODr. Maria L. Maccecchini, Ph.D.
Number of employees8
Security typeOrdinary Share
Fiscal year-endJan 29
Address101 Lindenwood Drive, Suite 225
CityMALVERN
Stock exchangeNYSE Consolidated
CountryUnited States of America
Postal code19355
Phone14848753192
Websitehttps://www.annovisbio.com/
Ticker SymbolANVS
IPO dateJan 29, 2020
CEODr. Maria L. Maccecchini, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Michael B. Hoffman
Mr. Michael B. Hoffman
Independent Chairman of the Board
Independent Chairman of the Board
1.67M
+1.52%
Mr. Andrew Walsh
Mr. Andrew Walsh
Vice President - Finance, Principal Financial Officer
Vice President - Finance, Principal Financial Officer
500.00
--
Dr. Maria L. Maccecchini, Ph.D.
Dr. Maria L. Maccecchini, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
--
--
Dr. Claudine E. Bruck, Ph.D.
Dr. Claudine E. Bruck, Ph.D.
Independent Director
Independent Director
--
--
Mr. Reid S. Mccarthy
Mr. Reid S. Mccarthy
Independent Director
Independent Director
--
--
Mr. Mark White
Mr. Mark White
Director, Chief Business Officer
Director, Chief Business Officer
--
--
Eve Damiano
Eve Damiano
Senior Vice President - Regulatory
Senior Vice President - Regulatory
--
--
,
,
Vice President - Process Chemistry
Vice President - Process Chemistry
--
--
Cheng Fang
Cheng Fang
Senior Vice President - Research and Development
Senior Vice President - Research and Development
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Michael B. Hoffman
Mr. Michael B. Hoffman
Independent Chairman of the Board
Independent Chairman of the Board
1.67M
+1.52%
Mr. Andrew Walsh
Mr. Andrew Walsh
Vice President - Finance, Principal Financial Officer
Vice President - Finance, Principal Financial Officer
500.00
--
Dr. Maria L. Maccecchini, Ph.D.
Dr. Maria L. Maccecchini, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
--
--
Dr. Claudine E. Bruck, Ph.D.
Dr. Claudine E. Bruck, Ph.D.
Independent Director
Independent Director
--
--
Mr. Reid S. Mccarthy
Mr. Reid S. Mccarthy
Independent Director
Independent Director
--
--
Mr. Mark White
Mr. Mark White
Director, Chief Business Officer
Director, Chief Business Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Jul 19
Updated: Sat, Jul 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Hoffman (Michael B)
8.57%
Maccecchini (Maria-Luisa)
5.72%
Heights Capital Management, Inc.
5.13%
The Vanguard Group, Inc.
3.33%
Two Sigma Investments, LP
1.33%
Other
75.93%
Shareholders
Shareholders
Proportion
Hoffman (Michael B)
8.57%
Maccecchini (Maria-Luisa)
5.72%
Heights Capital Management, Inc.
5.13%
The Vanguard Group, Inc.
3.33%
Two Sigma Investments, LP
1.33%
Other
75.93%
Shareholder Types
Shareholders
Proportion
Individual Investor
14.69%
Investment Advisor
11.83%
Investment Advisor/Hedge Fund
1.76%
Hedge Fund
1.75%
Research Firm
0.51%
Family Office
0.10%
Bank and Trust
0.05%
Pension Fund
0.03%
Other
69.28%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
103
5.97M
30.62%
-274.28K
2025Q1
104
5.95M
41.64%
-106.94K
2024Q4
93
4.41M
22.61%
-199.92K
2024Q3
85
4.03M
23.62%
-296.86K
2024Q2
80
3.84M
23.67%
-697.75K
2024Q1
77
3.92M
38.68%
-550.67K
2023Q4
77
3.92M
40.01%
-464.08K
2023Q3
81
3.83M
42.48%
-299.71K
2023Q2
104
3.90M
43.31%
-104.02K
2023Q1
106
3.34M
40.86%
-680.15K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Hoffman (Michael B)
1.67M
8.57%
+25.00K
+1.52%
Jun 13, 2025
Maccecchini (Maria-Luisa)
1.11M
5.72%
+46.00K
+4.31%
Jun 04, 2025
Heights Capital Management, Inc.
1.00M
5.13%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
647.92K
3.33%
+181.64K
+38.96%
Mar 31, 2025
Two Sigma Investments, LP
259.14K
1.33%
+248.22K
+2272.43%
Mar 31, 2025
UBS Financial Services, Inc.
160.88K
0.83%
+112.14K
+230.10%
Mar 31, 2025
Geode Capital Management, L.L.C.
152.61K
0.78%
+53.05K
+53.28%
Mar 31, 2025
Susquehanna International Group, LLP
127.70K
0.66%
+72.39K
+130.88%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
99.49K
0.51%
-1.29K
-1.28%
Mar 31, 2025
Consilium Associates
97.82K
0.5%
-700.00
-0.71%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Micro-Cap ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
